Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;19(3):363-372.
doi: 10.1007/s11307-017-1056-z.

Molecular Imaging in Nanotechnology and Theranostics

Affiliations
Review

Molecular Imaging in Nanotechnology and Theranostics

Chrysafis Andreou et al. Mol Imaging Biol. 2017 Jun.

Abstract

The fields of biomedical nanotechnology and theranostics have enjoyed exponential growth in recent years. The "Molecular Imaging in Nanotechnology and Theranostics" (MINT) Interest Group of the World Molecular Imaging Society (WMIS) was created in order to provide a more organized and focused forum on these topics within the WMIS and at the World Molecular Imaging Conference (WMIC). The interest group was founded in 2015 and was officially inaugurated during the 2016 WMIC. The overarching goal of MINT is to bring together the many scientists who work on molecular imaging approaches using nanotechnology and those that work on theranostic agents. MINT therefore represents scientists, labs, and institutes that are very diverse in their scientific backgrounds and areas of expertise, reflecting the wide array of materials and approaches that drive these fields. In this short review, we attempt to provide a condensed overview over some of the key areas covered by MINT. Given the breadth of the fields and the given space constraints, we have limited the coverage to the realm of nanoconstructs, although theranostics is certainly not limited to this domain. We will also focus only on the most recent developments of the last 3-5 years, in order to provide the reader with an intuition of what is "in the pipeline" and has potential for clinical translation in the near future.

Keywords: Imaging; MINT; Nanoparticles; Theranostic; WMIS.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: M.F.K. is an inventor on several pending patents related to Raman nanoparticles, Raman detection and theranostic hardware, as well as radiolabeling of silica particles, and is a co-founder of RIO Imaging, Inc., a startup company that has licensed several of these patents.

Figures

Fig. 1
Fig. 1
Through their modular structure, nanoparticles can incur specific biological interactions and deliver targeted therapy using intrinsic markers or external stimuli.
Fig. 2
Fig. 2
Nanoparticles of different materials, with many applications, are available at our fingertips.

References

    1. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016;33:2373–2387. - PubMed
    1. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioengineering & Translational Medicine. 2016;1:10–29. - PMC - PubMed
    1. Stylianopoulos T. Intelligent drug delivery systems for the treatment of solid tumors. Eur J Nanomed. 2016;8:9–16.
    1. Kircher MF, Willmann JK. Molecular body imaging: MR imaging, CT, and US. Part II. Applications. Radiology. 2012;264:349–368. - PubMed
    1. Kircher MF, Willmann JK. Molecular body imaging: MR imaging, CT, and US. part I. principles. Radiology. 2012;263:633–643. - PMC - PubMed

Publication types